Synthesis of a dehydrodieugenol B derivative as a lead compound for visceral leishmaniasis—mechanism of action and in vivo pharmacokinetic studies
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00831-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Maiara Amaral und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Physiopathology, Instituto Butantan, São Paulo, Brazil. Hauptthemen laut MEDLINE: Leishmaniasis, Visceral, Leishmania infantum, Antiprotozoal Agents, Reactive Oxygen Species. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Abstract (Originalsprache)
Leishmaniasis is a parasitic neglected tropical disease, affecting 12 million people. Available treatments present several limitations, with an increasing number of resistance cases. In the search for new chemotherapies, the natural product dehydrodieugenol B was used as a scaffold for the synthesis of a series of derivatives, resulting in the discovery of the promising analog [4-(4-(5-allyl-3-methoxy-2-((4-methoxybenzyl)oxy)phenoxy)-3-methoxybenzyl)morpholine, 1 ]. In this work, we investigated the effect of compound 1 on cell signaling in Leishmania (L.) infantum , culminating in cell death, as well as its immunomodulatory effect in the host cell. Additionally, we performed a pharmacokinetic profile study in an animal model. After treatment, compound 1 induced the alkalinization of acidocalcisomes and concomitant Ca 2+ release in the parasite. These events may induce depolarization of the mitochondrial potential, with successive collapse of the bioenergetic system, leading to a reduction of ATP and reactive oxygen species (ROS) levels. The analysis of total proteins and protein profile by matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF/MS) demonstrated that compound 1 also altered the parasite proteins after treatment. Transmission electron microscopy studies revealed ultrastructural damage to mitochondria; together, these data suggest that compound 1 may promote autophagic cell death. Additionally, compound 1 also induced an immunomodulatory effect in host cells, with a reduction of Th1 and Th2 cytokine response, characterizing an anti-inflammatory compound. The obtained pharmacokinetic profile in rats enhances the potential of the compound, with a mean plasma half-life (T 1/2 ) of 21 h. These data reinforce the potential of compound 1 as a new lead for future efficacy studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Physiopathology, Instituto Butantan, São Paulo, Brazil.
- Instituto de Medicina Tropical, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Oxford, United Kingdom.
- Laboratory of Pharmacology and Pharmaceutical Care, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
- Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Institute of Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal.
- Laboratório de Pesquisa do Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
ORCID-Profile: Ana Fortuna, Edward A Anderson, Andre G Tempone
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Zitieren
APA
Amaral, M., Romanelli, M. M., Asiki, H., Bicker, J., Lage, D. P., Freitas, C. S., Taniwaki, N. N., Lago, J. H. G., Coelho, E. A. F., Falcão, A., Fortuna, A., Anderson, E. A., & Tempone, A. G. (2024). Synthesis of a dehydrodieugenol B derivative as a lead compound for visceral leishmaniasis—mechanism of action and in vivo pharmacokinetic studies. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00831-24
Vancouver
Amaral M, Romanelli MM, Asiki H, Bicker J, Lage DP, Freitas CS, et al. Synthesis of a dehydrodieugenol B derivative as a lead compound for visceral leishmaniasis—mechanism of action and in vivo pharmacokinetic studies. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00831-24
BibTeX
@article{Amaral2024,
author = {Amaral, Maiara and Romanelli, Maiara M and Asiki, Hannah and Bicker, Joana and Lage, Daniela P and Freitas, Camila S and Taniwaki, Noemi N and Lago, Joao Henrique G and Coelho, Eduardo A F and Falcão, Amílcar and Fortuna, Ana and Anderson, Edward A and Tempone, Andre G},
title = {Synthesis of a dehydrodieugenol B derivative as a lead compound for visceral leishmaniasis—mechanism of action and in vivo pharmacokinetic studies},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00831-24}
}
EUVIMED